Analyst Profile

Followed by 25 followers
.
Eliana Merle

Eliana Merle

UBS
Wall Street Analyst
#6,568 out of 8,166 Wall Street Analysts
#19,468 out of 24,458 experts

Success Rate

40%
35 out of 88 transactions made a profit

Average Return

-3.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Eliana Merle's trades since 2018 and holding each position for 1 Year would result in 39.77% of your transactions generating a profit, with an average return of -3.0% per rating.

Stock Rating Distribution

155Ratings
81.94% Buy
18.06% Hold
0.00% Sell
Distribution of Eliana Merle's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
CymaBay Therapeutics Inc
(CBAY)
Rating:Buy
Date:Mar 13, 2020 - Mar 13, 2021
Return:+213.80%
The most profitable rating made by Eliana Merle

Eliana Merle's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Vertex Pharmaceuticals
Sep 28, 2018
Buy
Reiterated
$217.00
(-31.68% Downside)
1Ratings
0%
-13.40%
Aadi Bioscience
Mar 18, 2019
Buy
Reiterated
$8.00
(-40.25% Downside)
4Ratings
0%
-80.30%
ProQR
Dec 11, 2019
Buy
Reiterated
$40.00
(2736.88% Upside)
8Ratings
0%
-52.88%
Apellis Pharmaceuticals
Jan 07, 2020
Buy
Reiterated
$54.00
(9.36% Upside)
3Ratings
100%
+63.70%
ALXN
Alexion Pharmaceuticals
Apr 27, 2020
Hold
Initiated
1Ratings
0.00%
CymaBay Therapeutics
Aug 03, 2020
Buy
Reiterated
$20.00
(379.62% Upside)
15Ratings
11%
-32.88%
Durect
Aug 04, 2020
Buy
Reiterated
$5.00
(1182.05% Upside)
5Ratings
0%
-28.08%
BioMarin Pharmaceutical
Aug 05, 2020
Buy
Reiterated
$129.00
(24.60% Upside)
26Ratings
50%
-2.01%
Gilead Sciences
Aug 19, 2020
Buy
Reiterated
$84.00
(-4.52% Downside)
1Ratings
100%
+13.90%
Galapagos
Aug 19, 2020
Hold
Reiterated
$134.00
(244.30% Upside)
10Ratings
100%
+107.67%
List of latest recommendations made by Eliana Merle. Click to expand and see Eliana Merle's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >